Modulight Oyj

Modulight Oyj has a liquidity position characterized by a current ratio of 4.46, indicating strong short-term liquidity, supported by EUR 9.65 million in cash and equivalents. However, the company reported negative operating and free cash flows of EUR -1.75 million and EUR -4.44 million, respectively, suggesting ongoing operational cash burn. The debt-to-equity ratio of 0.06 reflects a conservative capital structure with minimal leverage. Profitability metrics show significant underperformance relative to industry norms. The company reported a return on equity (ROE) of -10.31% and a return on assets (ROA) of -9.37%, both well below the typical positive returns expected in the Advanced Medical Equipment & Technology sector. Gross profit of EUR 9.34 million was insufficient to cover operating expenses, resulting in an operating loss of EUR -4.65 million. Geographic and segment exposure is not explicitly detailed in the financial snapshot, but the company's operations span global markets, with subsidiaries in the USA and China. Revenue concentration data is not provided, but the absence of disclosed segment breakdowns suggests a lack of transparency in revenue diversification. Growth trajectory appears muted, with no specific revenue growth rates or outlooks provided in the financial data. The company's capital expenditures of EUR -4.31 million indicate ongoing investment in infrastructure, but without clear linkage to future revenue streams. Analyst price targets range from EUR 1.20 to EUR 2.00, with a mean of EUR 1.47, suggesting limited upside potential. Risk factors include liquidity risk due to negative operating cash flow and dilution risk, though both are currently assessed as low. No immediate filing-based flags were detected, but the company's negative net income of EUR -4.61 million raises concerns about long-term sustainability. Recent events include the absence of disclosed filings or transcripts in the provided data, limiting insight into management commentary or strategic shifts. The company's focus on biomedical lasers and customized solutions remains unchanged, but financial performance has not yet translated into profitability.